MX2021004173A - Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. - Google Patents
Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.Info
- Publication number
- MX2021004173A MX2021004173A MX2021004173A MX2021004173A MX2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A MX 2021004173 A MX2021004173 A MX 2021004173A
- Authority
- MX
- Mexico
- Prior art keywords
- combinations
- staphylococcus aureus
- protein
- aureus antibodies
- antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a combinaciones de anticuerpos anti-Staphylococcus aureus que incluyen combinaciones de anticuerpos que se unen a la proteína de la toxina alfa (AT), la proteína del factor de aglutinación A (ClfA), y/o al menos una proteína leucotoxina de S. aureus. También se proporcionan en el presente documento métodos para tratar y prevenir infecciones que comprenden administrar las combinaciones de anticuerpos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862743490P | 2018-10-09 | 2018-10-09 | |
US201962833297P | 2019-04-12 | 2019-04-12 | |
PCT/US2019/055143 WO2020076789A2 (en) | 2018-10-09 | 2019-10-08 | Combinations of anti-staphylococcus aureus antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021004173A true MX2021004173A (es) | 2021-09-08 |
Family
ID=70051346
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021004173A MX2021004173A (es) | 2018-10-09 | 2019-10-08 | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11168133B2 (es) |
EP (1) | EP3864041A2 (es) |
JP (1) | JP2022512647A (es) |
KR (1) | KR20210072057A (es) |
CN (1) | CN113164602A (es) |
AU (1) | AU2019357983A1 (es) |
BR (1) | BR112021006622A2 (es) |
CA (1) | CA3115633A1 (es) |
MX (1) | MX2021004173A (es) |
TW (1) | TW202035443A (es) |
WO (1) | WO2020076789A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6694269B2 (ja) * | 2012-11-06 | 2020-05-13 | メディミューン,エルエルシー | S.アウレウス(S.aureus)表面決定基に対する抗体 |
WO2020023644A2 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
TW202028232A (zh) | 2018-10-09 | 2020-08-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
CN117771379A (zh) * | 2023-10-25 | 2024-03-29 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源抗体与抗生素的组合 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US7658921B2 (en) | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
ES2372686T3 (es) | 2001-01-26 | 2012-01-25 | Inhibitex, Inc. | Anitcuerpos monoclonales dirigidos contra la proteína clfa y modo de empleo en el tratamiento y prevención de infecciones. |
WO2004006955A1 (en) | 2001-07-12 | 2004-01-22 | Jefferson Foote | Super humanized antibodies |
US20030226155A1 (en) | 2001-08-30 | 2003-12-04 | Biorexis Pharmaceutical Corporation | Modified transferrin-antibody fusion proteins |
US20040014194A1 (en) | 2002-03-27 | 2004-01-22 | Schering Corporation | Beta-secretase crystals and methods for preparing and using the same |
ATE458006T1 (de) | 2003-05-14 | 2010-03-15 | Kenta Biotech Ag | Humaner monoklonaler antikörper spezifisch für lipopolysacchariden (lps) des serotyps iats o6 von pseudomonas aeruginosa |
CN1324049C (zh) | 2003-08-04 | 2007-07-04 | 中国疾病预防控制中心病毒病预防控制所 | 人源抗sars冠状病毒基因工程抗体 |
SG172616A1 (en) | 2004-04-13 | 2011-07-28 | Hoffmann La Roche | Anti-p-selectin antibodies |
TW200813091A (en) | 2006-04-10 | 2008-03-16 | Amgen Fremont Inc | Targeted binding agents directed to uPAR and uses thereof |
WO2007145689A1 (en) | 2006-06-12 | 2007-12-21 | Nabi Biopharmaceuticals | Use of alpha-toxin for treating and preventing staphylococcus infections |
US8603950B2 (en) | 2007-02-20 | 2013-12-10 | Anaptysbio, Inc. | Methods of generating libraries and uses thereof |
JP5718640B2 (ja) | 2007-08-21 | 2015-05-13 | アムジエン・インコーポレーテツド | ヒトc−fms抗原結合性タンパク質 |
CA2697538C (en) | 2007-08-31 | 2019-02-12 | University Of Chicago | Methods and compositions related to immunizing against staphylococcal lung diseases and conditions |
BRPI0914005A2 (pt) | 2008-07-02 | 2015-11-17 | Emergent Product Dev Seattle | proteínas antagonistas tnf-alfa de ligação a alvos múltiplos |
EP2208787A1 (en) | 2009-01-19 | 2010-07-21 | Université de Liège | A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted |
MX337590B (es) | 2009-01-29 | 2016-03-11 | Medimmune Llc | Anticuerpos anti il-6 humanos, con semivida in vivo prolongada y su uso en el tratamiento de oncologia, enfermedades autoinmunes y enfermedades inflamatorias. |
PL3444268T3 (pl) | 2010-05-05 | 2022-04-19 | New York University | Leukocydyny staphylococcus aureus, kompozycje terapeutyczne i ich zastosowania |
BR112013020086B1 (pt) | 2011-02-08 | 2020-12-08 | Medimmune, Llc | Anticorpo isolado ou seu fragmento de ligação a antígeno, composição compreendendo o anticorpo ou fragmento de ligação a antígeno, kit, uso de uma quantidade eficaz de um anticorpo ou seu fragmento de ligação a antígeno e método para inibir a formação da oligômeros de alfatoxina |
JP6694269B2 (ja) | 2012-11-06 | 2020-05-13 | メディミューン,エルエルシー | S.アウレウス(S.aureus)表面決定基に対する抗体 |
KR20210083389A (ko) | 2012-11-06 | 2021-07-06 | 메디뮨 엘엘씨 | 에스.아우레우스 연관 질병의 치료 방법 |
BR112016008275A2 (pt) | 2013-10-17 | 2017-10-03 | Arsanis Biosciences Gmbh | Anticorpo com reatividade cruzada ao staphylococcus aureus, preparações farmacêuticas ou para diagnóstico compreendendo o anticorpo, anticorpo para uso médico e para diagnóstico, um ácido nucleico isolado que codifica o anticorpo, plasmideo ou cassete de expressao, e célula hospedeira compreendendo tal plasmideo ou cassete de expressao, método para produzir o anticorpo usando tal célula hospedeira, método para produzir variantes de anticorpos, um cristal formado por um monômero da hla ou lukd com dito anticorpo, um paratopo isolado do anticorpo, o epítopo isolado e uma molécula de ligação ligando especificamente ao dito epítopo, um método de triagem para identificar um ligante que se liga ao dito epítopo, um imunógeno compreendendo dito epítopo, e dito imunógeno usado para induzir uma resposta imune protetora |
US20170267780A1 (en) | 2014-05-16 | 2017-09-21 | Medimmune, Llc | Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties |
TWI719938B (zh) | 2014-06-19 | 2021-03-01 | 美商麥迪紐有限責任公司 | 多重細菌感染之治療 |
RU2017139800A (ru) * | 2015-04-17 | 2019-05-17 | Арсанис Байосайенсиз Гмбх | Комбинированный препарат антител против staphylococcus aureus |
US20190077851A1 (en) | 2015-10-30 | 2019-03-14 | Bruno Francois | Methods of using anti-alpha toxin antibody |
WO2020023644A2 (en) | 2018-07-24 | 2020-01-30 | Medimmune, Llc | Antibody directed against s. aureus clumping factor a (clfa) |
AU2019357983A1 (en) | 2018-10-09 | 2021-05-27 | Medimmune, Llc | Combinations of anti-staphylococcus aureus antibodies |
TW202028232A (zh) | 2018-10-09 | 2020-08-01 | 美商麥迪紐有限責任公司 | 針對金黃色葡萄球菌白血球毒素的抗體 |
-
2019
- 2019-10-08 AU AU2019357983A patent/AU2019357983A1/en active Pending
- 2019-10-08 BR BR112021006622-5A patent/BR112021006622A2/pt unknown
- 2019-10-08 MX MX2021004173A patent/MX2021004173A/es unknown
- 2019-10-08 CN CN201980078574.1A patent/CN113164602A/zh active Pending
- 2019-10-08 KR KR1020217013653A patent/KR20210072057A/ko unknown
- 2019-10-08 EP EP19871705.0A patent/EP3864041A2/en not_active Withdrawn
- 2019-10-08 US US16/596,388 patent/US11168133B2/en active Active
- 2019-10-08 JP JP2021519612A patent/JP2022512647A/ja active Pending
- 2019-10-08 WO PCT/US2019/055143 patent/WO2020076789A2/en active Application Filing
- 2019-10-08 CA CA3115633A patent/CA3115633A1/en active Pending
- 2019-10-08 TW TW108136341A patent/TW202035443A/zh unknown
-
2021
- 2021-10-01 US US17/491,889 patent/US20220089699A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20200109189A1 (en) | 2020-04-09 |
US20220089699A1 (en) | 2022-03-24 |
KR20210072057A (ko) | 2021-06-16 |
CN113164602A (zh) | 2021-07-23 |
CA3115633A1 (en) | 2020-04-16 |
TW202035443A (zh) | 2020-10-01 |
AU2019357983A1 (en) | 2021-05-27 |
US11168133B2 (en) | 2021-11-09 |
JP2022512647A (ja) | 2022-02-07 |
WO2020076789A3 (en) | 2020-10-22 |
WO2020076789A2 (en) | 2020-04-16 |
EP3864041A2 (en) | 2021-08-18 |
BR112021006622A2 (pt) | 2021-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021004173A (es) | Combinaciones de anticuerpos dirigidos contra staphylococcus aureus. | |
ZA202211057B (en) | Anti-trem2 antibodies and methods of use thereof | |
PH12020551930A1 (en) | Anti-sirpa antibodies and methods of use thereof | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
WO2017152102A3 (en) | Anti-trem1 antibodies and methods of use thereof | |
EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
BR112016028043A2 (pt) | composições farmacêuticas, e transportador farmaceuticamente aceitável e anticorpo monoclonal para igg3 humana ou humanizada | |
EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
EA201991643A1 (ru) | Человеческие антитела к токсину гемолизину а s.aureus | |
MX2021004114A (es) | Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. | |
TW201613575A (en) | Treatment of polybacterial infections | |
WO2020023644A3 (en) | Antibody directed against s. aureus clumping factor a (clfa) | |
WO2020006374A3 (en) | Anti-sirp-beta1 antibodies and methods of use thereof | |
CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
MX2022007231A (es) | Anticuerpos anti-mertk y metodos de uso de los mismos. | |
MX2021012692A (es) | Anticuerpos anti-mertk y sus metodos de uso. | |
PH12021550332A1 (en) | Anti-cd33 antibodies and methods of use thereof | |
WO2017075188A3 (en) | Methods of using anti-alpha toxin antibody | |
MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
EA201990222A1 (ru) | Антитела к o2 и пути их применения | |
EA201992348A1 (ru) | АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1 | |
MA55558A (fr) | Anticorps anti-cd73, anti-pd-l1 et chimiothérapie de traitement de tumeurs | |
MX2022003762A (es) | Molécula de unión específica para el factor inhibidor de la leucemia (lif) y uso de la misma. | |
MX2020012245A (es) | Sindrome de choque toxico estreptococico. | |
EA202191388A1 (ru) | Лечение головной боли при избыточном применении лекарственных препаратов антителами к cgrp или cgrp-r |